FIELD: medicine.
SUBSTANCE: present invention refers to pharmaceutics and medicine and concerns applications of bicyclic pyrimidines for making medical products to be used for HCV inhibition, prevention or treatment of the HCV-related conditions.
EFFECT: invention expands range of products for affecting a live organism, and also presents compounds which are active with respect to both natural HCV virus, and common resistant HCV viruses.
11 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HETEROBICYCLIC HEPATITIS C VIRUS (HCV) INHIBITORS | 2006 |
|
RU2405783C2 |
| NOVEL AMMONIUM DERIVATIVES, A METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | 2016 |
|
RU2743098C2 |
| ANTIVIRAL COMPOUND | 2006 |
|
RU2441010C2 |
| SUBSTITUTED HETEROCYCLIC SULPHONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | 2014 |
|
RU2675792C2 |
| BRUTON'S TYROSINE KINASE INHIBITORS | 2013 |
|
RU2619465C2 |
| BICYCLIC PYRIDINES AND PYRIMIDINES AS KINASE P38 INHIBITORS | 2003 |
|
RU2301233C2 |
| CXCR7 ANTAGONISTS | 2013 |
|
RU2649004C2 |
| TRIAZOLO-PYRIMIDINE COMPOUNDS AND THEIR USE | 2019 |
|
RU2802866C2 |
| PIPERIDINE DERIVATIVES | 2011 |
|
RU2554353C2 |
| PHOSPHOINOSITIDE3-KINASE INHIBITING COMPOUNDS AND METHODS FOR USE THEREOF | 2007 |
|
RU2470936C2 |
